Hypera (HYPE3.SA) Stock Price
Hypera Price
Over the last 19 years Hypera grew revenue by 17.2% annually, reaching 7.70 B BRL. Earnings per share have grown at 7.2% per year over the last 16 years. For Hypera, the net margin of 15.5% is down versus 22.4% a few years ago. At today's price the dividend yield works out to roughly 5.21%. The payout ratio is around 63% of earnings. The dividend has grown at 17.6% per year over the past 14 years. The consensus 12-month price target for Hypera is 30.09 BRL, about 34.0% above where the stock trades today. Of 19 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 12% above its 52-week low.
Hypera stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Hypera over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Hypera stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Hypera's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Hypera Price |
|---|---|
| 9/2/2026 | 22.46 BRL |
| 9/1/2026 | 21.75 BRL |
| 8/31/2026 | 21.47 BRL |
| 8/28/2026 | 21.14 BRL |
| 8/27/2026 | 21.59 BRL |
| 8/26/2026 | 22.01 BRL |
| 8/25/2026 | 21.80 BRL |
| 8/24/2026 | 21.53 BRL |
| 8/21/2026 | 21.17 BRL |
| 8/20/2026 | 20.73 BRL |
| 8/19/2026 | 20.76 BRL |
| 8/18/2026 | 20.72 BRL |
| 8/17/2026 | 20.98 BRL |
| 8/14/2026 | 21.51 BRL |
| 8/13/2026 | 21.84 BRL |
| 8/12/2026 | 21.57 BRL |
| 8/11/2026 | 21.16 BRL |
| 8/10/2026 | 21.71 BRL |
| 8/7/2026 | 21.60 BRL |
| 8/6/2026 | 21.33 BRL |
| 8/5/2026 | 21.52 BRL |
| 8/4/2026 | 21.54 BRL |
| 8/3/2026 | 21.52 BRL |
| 7/31/2026 | 21.27 BRL |
| 7/30/2026 | 21.65 BRL |
| 7/29/2026 | 21.03 BRL |
| 7/28/2026 | 21.44 BRL |
| 7/27/2026 | 21.06 BRL |
| 7/24/2026 | 20.23 BRL |
| 7/23/2026 | 20.10 BRL |
Hypera Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Hypera Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB BRL |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB BRL |
| EBITB BRL |
| EBIT MARGIN% |
| NET INCOMEB BRL |
| NET INCOME GROWTH% |
| DIVIDENDDIV.BRL |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.96 | 3.29 | 3.64 | 3.72 | 3.29 | 4.09 | 5.94 | 7.55 | 7.91 | 7.44 | 7.70 | 9.23 | 10.26 | 11.28 | 13.03 | 13.57 |
| -36.84 | 11.23 | 10.64 | 2.36 | -11.55 | 24.10 | 45.23 | 27.10 | 4.88 | -5.96 | 3.45 | 19.86 | 11.21 | 9.92 | 15.49 | 4.14 |
| 74.76 | 74.24 | 74.52 | 71.56 | 63.30 | 64.31 | 64.04 | 63.09 | 63.12 | 58.87 | 59.03 | 59.03 | 59.03 | 59.03 | 59.03 | 59.03 |
| 2.21 | 2.44 | 2.71 | 2.67 | 2.09 | 2.63 | 3.80 | 4.76 | 5.00 | 4.38 | 4.55 | 5.45 | 6.06 | 6.66 | 7.69 | 8.01 |
| 0.88 | 1.07 | 1.17 | 1.28 | 1.13 | 1.40 | 2.04 | 2.64 | 2.29 | 1.95 | 1.94 | 3.31 | 3.90 | 4.16 | 4.80 | 4.85 |
| 29.87 | 32.60 | 32.02 | 34.37 | 34.30 | 34.20 | 34.29 | 35.01 | 28.87 | 26.20 | 25.24 | 35.85 | 37.98 | 36.87 | 36.86 | 35.78 |
| 0.56 | 1.18 | 0.96 | 1.13 | 1.16 | 1.30 | 1.33 | 1.70 | 1.65 | 1.34 | 1.20 | 1.69 | 1.99 | 2.34 | 2.86 | 2.90 |
| 39.05 | 110.55 | -18.10 | 17.12 | 3.10 | 11.25 | 2.70 | 27.52 | -2.89 | -18.64 | -10.82 | 41.17 | 18.02 | 17.63 | 21.90 | 1.44 |
| – | 0.67 | 1.95 | – | – | – | – | – | – | – | – | 1.05 | 1.26 | 1.52 | – | – |
| – | – | 191.04 | – | – | – | – | – | – | – | – | – | 20.00 | 20.63 | – | – |
| 628.81 | 624.90 | 631.85 | 632.19 | 679.54 | 629.73 | 635.68 | 650.56 | 628.81 | 647.21 | 642.89 | 642.89 | 642.89 | 642.89 | 642.89 | 642.89 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Hypera generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Hypera retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Hypera's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Hypera has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Hypera's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Hypera stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Hypera Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Hypera business model & stock analysis
Hypera SWOT Analysis
Strengths
- Strong market presence: Hypera SA is a leading pharmaceutical company in its domestic market.
- Extensive product portfolio: The company offers a wide range of pharmaceutical products across various therapeutic areas.
- Strong financial performance: Hypera SA has consistently delivered strong financial results, reflecting its efficient operations and robust sales.
Weaknesses
- Dependency on the domestic market: Hypera SA relies heavily on its domestic market for revenue generation, making it vulnerable to any adverse economic or regulatory changes in the country.
- Product concentration: The company's revenue is highly dependent on a few key products, which exposes it to significant risks in case of any product-related issues or competition.
- Limited global presence: Hypera SA has limited international presence, restricting its opportunities for growth in global markets.
Opportunities
- Expansion into international markets: Hypera SA can explore new markets and expand its presence globally, leveraging its strong product portfolio and expertise.
- Increasing healthcare expenditure: The growing focus on healthcare and rising disposable incomes in emerging markets present opportunities for Hypera SA to tap into new customer segments.
- Investment in research and development (R&D): The company can invest in R&D to develop innovative products and maintain its competitive edge in the pharmaceutical industry.
Threats
- Intense competition: The pharmaceutical industry is highly competitive, and Hypera SA faces competition from both local and multinational companies, which may impact its market share and profitability.
- Regulatory challenges: Stringent regulations and pricing pressures in the pharmaceutical sector can pose challenges for Hypera SA, affecting its pricing strategies and profitability.
- Intellectual property risks: The company's reliance on patents for its products exposes it to the risk of patent expiration and potential generic competition.
Hypera Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Hypera historical P/E ratio, EBIT multiple, and P/S ratio
Hypera annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Hypera shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Hypera stock splits
Hypera Dividend History
13 years of dividend payments
Hypera dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Hypera dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Hypera forecasts and price targets in September 2026
Analyst Price Targets 2026Hypera Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 4/25/2024 | 0.61BRL | - | 1.88 BBRL | - | 2024 Q1 |
| 2/14/2024 | 0.67BRL | - | 2.13 BBRL | - | 2023 Q4 |
| 7/26/2023 | 0.79BRL | - | 2.17 BBRL | - | 2023 Q2 |
| 4/26/2023 | 0.62BRL | - | 1.79 BBRL | - | 2023 Q1 |
| 2/22/2023 | 0.73BRL | - | 2.04 BBRL | - | 2022 Q4 |
| 10/27/2022 | 0.72BRL | - | 2.02 BBRL | - | 2022 Q3 |
| 7/28/2022 | 0.67BRL | - | 1.90 BBRL | - | 2022 Q2 |
| 4/28/2022 | 0.56BRL | - | 1.49 BBRL | - | 2022 Q1 |
| 2/24/2022 | 0.62BRL | - | 1.65 BBRL | - | 2021 Q4 |
| 10/24/2021 | 0.64BRL | - | 1.60 BBRL | - | 2021 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Hypera stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Hypera shareholder structure
| % | Name |
|---|---|
27.48118% | |
14.63758% | |
10.94417% | |
5.97680% | |
4.98327% | |
4.94201% |
Hypera Beneficial Ownership Filings (SEC 13D/G)
Hypera Executives and Management Board
14 members · avg. age 53 · 29 % women
Management
Mr. Breno Toledo De Oliveira (49)
Chief Executive Officer · since 2011
Mr. Ramon Sanches Frutuoso Silva (37)
Chief Financial Officer
Ms. Juliana Aguinaga Damiao Salem (41)
Executive Officer - Legal Department
Mr. Rafael Vito Batista (39)
Executive Officer
Mr. Adalmario Do Couto (43)
Investor Relations Officer, Business Development Officer
Board of Directors
Mr. Alvado Stainfeld Link (54)
Chairman of the Board
Ms. Luciana Cavalheiro De Queiroz (50)
Member of the Board of Directors
Mr. Esteban Malpica Fomperosa (75)
Member of the Board of Directors
Mr. Bernardo Malpica Hernandez (59)
Member of the Board of Directors
Mr. Hugo Barreto Sodre Leal (49)
Member of the Board of Directors
Mr. Mauro Gentile Rodrigues Da Cunha (53)
Independent Member of the Board of Directors
Frequently asked questions about Hypera
Hypera SA, a leading pharmaceutical company based in Brazil, operates on a robust business model. The core of their business involves the manufacturing, marketing, and distribution of a wide range of pharmaceutical products. Hypera SA specializes in both prescription and over-the-counter medications, catering to various therapeutic areas. They also produce medical-hospital products and non-pharmaceutical items such as personal hygiene and beauty care products. With a focus on innovation and quality, Hypera SA aims to improve the health and well-being of individuals across the country. As a prominent player in the pharmaceutical industry, Hypera SA continues to expand its product portfolio, enhance operational efficiency, and ensure customer satisfaction.
Hypera SA is primarily active in the pharmaceutical industry.
The main competitors of Hypera SA in the market are pharmaceutical companies such as Aché Laboratórios, EMS Pharma, and Eurofarma.
Hypera SA, formerly known as Hypermarcas SA, is a leading pharmaceutical company based in Brazil. Founded in 2001, Hypera has a rich history and has significantly grown over the years. It focuses on the development, production, and commercialization of pharmaceutical products, generic drugs, over-the-counter medications, and personal care items. Hypera has established a strong presence in the Brazilian market, offering a wide range of high-quality and affordable healthcare solutions. Its commitment to research and innovation has led to numerous successful product launches. Hypera SA continues to be a prominent player in the pharmaceutical industry, continuously expanding its portfolio and enhancing the well-being of consumers.
Hypera SA, a renowned company in the pharmaceutical industry, has accomplished several significant milestones throughout its journey. The company has successfully positioned itself as a leader in the Latin American market, expanding its presence across various countries. Hypera SA has consistently demonstrated its commitment to innovation and research, introducing numerous breakthrough pharmaceutical products. With strategic acquisitions and partnerships, the company has further strengthened its portfolio and market share. Hypera SA's relentless focus on quality control and strict adherence to regulatory standards has earned it a stellar reputation among industry experts and stakeholders. These achievements reflect Hypera SA's dedication to advancing healthcare solutions and driving long-term growth in the pharmaceutical sector.
Hypera SA is primarily present in Brazil.
Hypera SA represents a strong commitment to its corporate philosophy, which revolves around innovation, excellence, and integrity. With a focus on enhancing quality of life, Hypera SA aims to deliver innovative healthcare solutions to consumers. The company puts a strong emphasis on research and development, constantly striving to introduce new and effective products to market. By promoting a culture of excellence, Hypera SA seeks to provide top-notch customer service and quality-assured products. With a dedication to integrity, the company operates transparently and ethically, ensuring trust and reliability among its stakeholders. Hypera SA's values and corporate philosophy ultimately drive its mission to positively impact people's health and well-being.
Analysts currently set an average price target of 30.54 BRL for the Hypera stock (median: 30.09 BRL), implying +34.4 % versus the latest price. The consensus is based on 19 analyst ratings.
19 analysts currently rate the Hypera stock: 13 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Hypera to generate revenue of 9.23 B BRL and earnings per share of 2.62 BRL.
Converted at the current exchange rate, the Hypera share trades at 3.80 EUR (22.46 BRL).
The Brazilian company Hypera SA is a leading manufacturer and distributor of pharmaceuticals, dietary supplements, cosmetics, and household products. It has been listed on the stock exchange since 2008 and has built a strong presence in the Brazilian market in recent years. Hypera SA operates in four business segments: Consumer Health, Pharma, Over-the-Counter medicines, and Cosmetics and Skincare products. The Consumer Health division offers a wide range of products such as vitamins, pain relievers, cough and cold medicines, as well as dietary supplements and baby food. Hypera SA's Pharma business includes prescription drugs, including medications for cardiovascular, diabetes, gastroenterology, and oncology patients. Additionally, the company also provides vaccines and medications for respiratory diseases. In the Over-the-Counter medicines segment, the company offers a wide range of non-prescription medications for colds, digestive issues, pain, and allergies. This includes diet and weight loss products, vitamins and minerals, as well as other supplements. Hypera SA also offers a variety of cosmetic and skincare products, including brands like Episol, Hair Fly, Monange, Neostrata, and Assolan. The company also operates a household products division, which includes brands like Vitasay, Tixan, and Blergh. The product range of Hypera SA is diverse, ranging from affordable mass-market products to more expensive premium brands. The company aims to reach a wide range of customers and has specialized in marketing products for the health and beauty segment. It has established relationships with major retail chains as well as pharmacies and other sales locations. Hypera SA strives to integrate innovation and technology into its business model. The company has a research and development team constantly developing and launching new products. It also invests in automation and digitization of its production facilities to improve the efficiency and quality of its products. Overall, Hypera SA's business model is focused on a wide product range and a strong brand presence. The company relies on price competition and innovation to strengthen its market position. As a leading provider of healthcare, cosmetic, and household products in Brazil, the company aims to expand internationally.
The expected revenue of Hypera is 9.23 B BRL. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Hypera is 1.69 B BRL. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Hypera is currently 8.56. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hypera stock.
The price-to-sales ratio (P/S) of Hypera is currently 1.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hypera stock.
The Eulerpool Quality Score for Hypera is 6/10.
The ISIN of Hypera is BRHYPEACNOR0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Hypera is HYPE3.SA. The ticker symbol is used to trade Hypera shares on the stock exchange.
Over the past 12 months, Hypera paid a dividend of 1.17 BRL . This corresponds to a dividend yield of about 5.21 %. For the coming 12 months, Hypera is expected to pay a dividend of 1.26 BRL.
The current dividend yield of Hypera is 5.21 %.
Hypera pays a dividend, distributed in the months of , , , .
Hypera paid dividends every year for the past 10 years.
For the upcoming 12 months, dividends amounting to 1.26 BRL are expected. This corresponds to a dividend yield of 5.62 %.
Hypera is assigned to the 'Health' sector.
In the year 2025, Hypera distributed 1.17 BRL as dividends.
The dividends of Hypera are distributed in BRL.
Hypera stock
Hypera Peer Group
Hypera Ticker
Hypera FIGI
All fundamentals and in-depth analysis of Hypera
Our stock analysis for Hypera stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hypera. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.